Cover Image
Market Research Report

Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2019

Published by GlobalData Product code 357851
Published Content info 274 Pages
Delivery time: 1-2 business days
Price
Back to Top
Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2019
Published: May 8, 2019 Content info: 274 Pages
Description

GlobalData's Medical Devices sector report, "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2019" provides an overview of Dry Powder Inhaler Devices currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Dry Powder Inhaler Devices pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Dry Powder Inhaler Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Dry Powder Inhaler Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Dry Powder Inhaler Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.
Table of Contents
Product Code: GDME0778EPD

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Dry Powder Inhaler Devices Overview

3 Products under Development

  • 3.1 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • 3.2 Dry Powder Inhaler Devices - Pipeline Products by Territory
  • 3.3 Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • 3.4 Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • 3.5 Dry Powder Inhaler Devices - Ongoing Clinical Trials

4 Dry Powder Inhaler Devices - Pipeline Products under Development by Companies

  • 4.1 Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
  • 4.2 Dry Powder Inhaler Devices - Pipeline Products by Stage of Development

5 Dry Powder Inhaler Devices Companies and Product Overview

  • 5.1 Acorda Therapeutics Inc Company Overview
  • 5.2 Adamis Pharmaceuticals Corp Company Overview
  • 5.3 Advent Pharmaceuticals Pty Ltd Company Overview
  • 5.4 Aespira Ltd. Company Overview
  • 5.5 AKELA Pharma Inc. (Inactive) Company Overview
  • 5.6 AstraZeneca Plc Company Overview
  • 5.7 Bayer AG Company Overview
  • 5.8 Boehringer Ingelheim GmbH Company Overview
  • 5.9 Circassia Pharmaceuticals Plc Company Overview
  • 5.10 Eli Lilly and Co Company Overview
  • 5.11 GlaxoSmithKline Plc Company Overview
  • 5.12 Lupin Pharmaceuticals Inc Company Overview
  • 5.13 MannKind Corp Company Overview
  • 5.14 Monash University Company Overview
  • 5.15 Nektar Therapeutics Company Overview
  • 5.16 Ology Bioservices Inc Company Overview
  • 5.17 OPKO Health Inc Company Overview
  • 5.18 OtiTopic LLC Company Overview
  • 5.19 Pharmaxis Ltd Company Overview
  • 5.20 Respira Therapeutics Inc Company Overview
  • 5.21 Sandoz International GmbH Company Overview
  • 5.22 Sheffield Hallam University Company Overview
  • 5.23 Spyryx Biosciences Inc Company Overview
  • 5.24 Sun Pharma Advanced Research Company Ltd Company Overview
  • 5.25 Teva Pharmaceutical Industries Ltd Company Overview
  • 5.26 University of Kansas Company Overview
  • 5.27 University of Sydney Company Overview
  • 5.28 University of Texas Medical Branch at Galveston Company Overview
  • 5.29 Vectura Group Plc Company Overview
  • 5.30 Verona Pharma Plc Company Overview
  • 5.31 Virginia Commonwealth University Company Overview

6 Dry Powder Inhaler Devices- Recent Developments

  • 6.1 May 02, 2019: Teva reports first quarter 2019 financial results
  • 6.2 May 01, 2019: GSK delivers sales of £7.7 billion +6% AER, +5% CER
  • 6.3 Apr 25, 2019: 3M reports first-quarter 2019 results; company initiates restructuring
  • 6.4 Apr 25, 2019: Orion Group Interim report January-March 2019
  • 6.5 Apr 24, 2019: Novartis starts 2019 with strong sales and double digit core operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded
  • 6.6 Apr 11, 2019: Fire at Orion's manufacturing plant in Turku
  • 6.7 Apr 10, 2019: Teva signs new $2.3 billion syndicated revolving credit facility
  • 6.8 Apr 09, 2019: Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
  • 6.9 Apr 02, 2019: Alcon announces Timothy Stonesifer as Chief Financial Officer
  • 6.10 Apr 02, 2019: 3M Drug Delivery Systems relocates UK R&D to new, state-of-the-art facility

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

  • Table 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Table 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Table 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Table 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Table 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
  • Table 6: Dry Powder Inhaler Devices Companies - Pipeline Products by Stage of Development
  • Table 7: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Table 8: Acorda Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: INBRIJA - Product Status
  • Table 10: INBRIJA - Product Description
  • Table 11: Adamis Pharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: Taper DPI - Product Status
  • Table 13: Taper DPI - Product Description
  • Table 14: Advent Pharmaceuticals Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 15: g60 Dry Powder Inhaler - Product Status
  • Table 16: g60 Dry Powder Inhaler - Product Description
  • Table 17: Aespira Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: resQhaler - Product Status
  • Table 19: resQhaler - Product Description
  • Table 20: AKELA Pharma Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • Table 21: Fentanyl TAIFUN Inhaler - Product Status
  • Table 22: Fentanyl TAIFUN Inhaler - Product Description
  • Table 23: AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 24: Duaklir Genuair Metered Dose Inhaler - Product Status
  • Table 25: Duaklir Genuair Metered Dose Inhaler - Product Description
  • Table 26: Bayer AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 27: Ciprofloxacin Dry Powder Inhaler - Product Status
  • Table 28: Ciprofloxacin Dry Powder Inhaler - Product Description
  • Table 29: Boehringer Ingelheim GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Next Generation Respimat Inhaler - Product Status
  • Table 31: Next Generation Respimat Inhaler - Product Description
  • Table 32: Circassia Pharmaceuticals Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Tiotropium bromide DPI - Product Status
  • Table 34: Tiotropium bromide DPI - Product Description
  • Table 35: Eli Lilly and Co Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Nasal Glucagon Delivery System - Product Status
  • Table 37: Nasal Glucagon Delivery System - Product Description
  • Table 38: GlaxoSmithKline Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: Gemini Multi-Dose Combination Inhaler - Product Status
  • Table 40: Gemini Multi-Dose Combination Inhaler - Product Description
  • Table 41: Lupin Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Tiotropium DPI - Product Status
  • Table 43: Tiotropium DPI - Product Description
  • Table 44: MannKind Corp Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: Dreamboat - Product Status
  • Table 46: Dreamboat - Product Description
  • Table 47: Treprostinil Technosphere - Product Status
  • Table 48: Treprostinil Technosphere - Product Description
  • Table 49: Monash University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 50: Aerosol Delivery System - Product Status
  • Table 51: Aerosol Delivery System - Product Description
  • Table 52: Nektar Therapeutics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 53: Nektar Dry Powder Inhaler - Amikacin - Product Status
  • Table 54: Nektar Dry Powder Inhaler - Amikacin - Product Description
  • Table 55: Ology Bioservices Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 56: GelVac Intranasal Powder Vaccine Delivery System - Product Status
  • Table 57: GelVac Intranasal Powder Vaccine Delivery System - Product Description
  • Table 58: NanoGENT - Product Status
  • Table 59: NanoGENT - Product Description
  • Table 60: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview

List of Figures

  • Figure 1: Dry Powder Inhaler Devices - Pipeline Products by Stage of Development
  • Figure 2: Dry Powder Inhaler Devices - Pipeline Products by Territory
  • Figure 3: Dry Powder Inhaler Devices - Pipeline Products by Regulatory Path
  • Figure 4: Dry Powder Inhaler Devices - Pipeline Products by Estimated Approval Date
  • Figure 5: Dry Powder Inhaler Devices - Ongoing Clinical Trials
Back to Top